SR-17018

SR-17018
Identifiers
	IUPAC name 5,6-dichloro-3-[1-[(4-chlorophenyl)methyl]piperidin-4-yl]-1H-benzimidazol-2-one;
CAS Number	2134602-45-0;
PubChem CID	130431397;
ChemSpider	67886365;
Chemical and physical data
Formula	C19H18Cl3N3O
Molar mass	410.72 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCC1N2C3=CC(=C(C=C3NC2=O)Cl)Cl)CC4=CC=C(C=C4)Cl;
	InChI InChI=1S/C19H18Cl3N3O/c20-13-3-1-12(2-4-13)11-24-7-5-14(6-8-24)25-18-10-16(22)15(21)9-17(18)23-19(25)26/h1-4,9-10,14H,5-8,11H2,(H,23,26); Key:LAGUDYUGRSQDKS-UHFFFAOYSA-N;

SR-17018 is a drug which acts as a biased agonist at the μ-opioid receptor, selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment. In animal studies it produces analgesic effects but with less respiratory depression and development of tolerance than conventional opioids.[1][2][3][4]

References

Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho JH, Acevedo-Canabal A, et al. (January 2020). "A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal". Neuropsychopharmacology. 45 (2): 416–425. doi:10.1038/s41386-019-0491-8. PMC 6901606. PMID 31443104.
Azevedo Neto J, Costanzini A, De Giorgio R, Lambert DG, Ruzza C, Calò G (August 2020). "Biased versus Partial Agonism in the Search for Safer Opioid Analgesics". Molecules. 25 (17): 3870. doi:10.3390/molecules25173870. PMC 7504468. PMID 32854452.
Podlewska S, Bugno R, Kudla L, Bojarski AJ, Przewlocki R (October 2020). "Molecular Modeling of µ Opioid Receptor Ligands with Various Functional Properties: PZM21, SR-17018, Morphine, and Fentanyl-Simulated Interaction Patterns Confronted with Experimental Data". Molecules. 25 (20): 4636. doi:10.3390/molecules25204636. PMC 7594085. PMID 33053718.
Pantouli F, Grim TW, Schmid CL, Acevedo-Canabal A, Kennedy NM, Cameron MD, et al. (December 2020). "Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain". Neuropharmacology: 108439. doi:10.1016/j.neuropharm.2020.108439. PMID 33345829. S2CID 229306872.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Grim TW, Schmid CL, Stahl EL, Pantouli F, Ho JH, Acevedo-Canabal A, et al. (January 2020). "A G protein signaling-biased agonist at the μ-opioid receptor reverses morphine tolerance while preventing morphine withdrawal". Neuropsychopharmacology. 45 (2): 416–425. doi:10.1038/s41386-019-0491-8. PMC 6901606. PMID 31443104.

[2] Azevedo Neto J, Costanzini A, De Giorgio R, Lambert DG, Ruzza C, Calò G (August 2020). "Biased versus Partial Agonism in the Search for Safer Opioid Analgesics". Molecules. 25 (17): 3870. doi:10.3390/molecules25173870. PMC 7504468. PMID 32854452.

[3] Podlewska S, Bugno R, Kudla L, Bojarski AJ, Przewlocki R (October 2020). "Molecular Modeling of µ Opioid Receptor Ligands with Various Functional Properties: PZM21, SR-17018, Morphine, and Fentanyl-Simulated Interaction Patterns Confronted with Experimental Data". Molecules. 25 (20): 4636. doi:10.3390/molecules25204636. PMC 7594085. PMID 33053718.

[4] Pantouli F, Grim TW, Schmid CL, Acevedo-Canabal A, Kennedy NM, Cameron MD, et al. (December 2020). "Comparison of morphine, oxycodone and the biased MOR agonist SR-17018 for tolerance and efficacy in mouse models of pain". Neuropharmacology: 108439. doi:10.1016/j.neuropharm.2020.108439. PMID 33345829. S2CID 229306872.

SR-17018

See also

References